Business Context and Reporting Period
This Form 8-K, dated January 29, 2021 and filed February 4, 2021, was filed by HealthCor Catalio Acquisition Corp., a Cayman Islands special purpose acquisition company. Although the request metadata identifies Hyperfine, Inc., the filing text identifies HealthCor Catalio Acquisition Corp. as the registrant.
The report concerns the completion of the registrant’s initial public offering and related private placement on January 29, 2021.
Key Financial Metrics and Liquidity
- The IPO comprised 20,700,000 Class A ordinary shares, including 2,700,000 shares issued pursuant to the underwriters’ fully exercised over-allotment option.
- The IPO price was $10.00 per share.
- HC Sponsor LLC purchased 614,000 Class A ordinary shares in a private placement.
- Aggregate net offering proceeds of $202.86 million, including certain private-placement proceeds, were deposited into a trust account.
- The trust account was established for the benefit of public shareholders and the IPO underwriters, with Continental Stock Transfer & Trust Company serving as trustee.
- The filing text does not provide clear values for revenue, profit, operating cash flow, margins, debt, or other operating performance metrics.
Material Changes and Transaction Terms
The material event was the completion of the IPO and private placement. Except for interest that may be released to pay income taxes, the offering proceeds generally may not be released to the company until completion of its initial business combination.
Public shareholders may receive redemption proceeds in connection with an initial business combination, certain amendments affecting redemption rights, or if the company does not complete a business combination within 24 months after the IPO closing.
An audited balance sheet as of January 29, 2021 reflecting receipt of the offering proceeds was filed as Exhibit 99.1.
Outlook, Risks, and Unusual Items
- The company had not yet identified or completed its initial business combination as of the filing.
- Offering proceeds are restricted in the trust account pending specified events, limiting their availability for general corporate purposes.
- If no business combination is completed within 24 months of the IPO closing, the public shares are generally subject to redemption, subject to applicable law.
- Completion of a future business combination, shareholder redemption activity, and any related amendments to the company’s governing documents may affect the amount of capital available after the transaction.
- The filing provides no operating guidance or earnings outlook.
Investor Verification Checklist
- Verify that HealthCor Catalio Acquisition Corp., rather than Hyperfine, Inc., is the registrant named in the filing.
- Review Exhibit 99.1 for the audited balance sheet and the detailed composition of cash, offering costs, and liabilities.
- Confirm the $202.86 million aggregate trust-account deposit and the number of IPO and private-placement shares issued.
- Review the company’s search for an initial business combination, including applicable timing, redemption, and shareholder-vote provisions.
- Confirm whether subsequent filings identify a target, amend the 24-month deadline, or change the trust-account or redemption terms.